Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension?

被引：9

作者：

Kaplan, NM ^{[1
]}

机构：

[1] Univ Texas, SW Med Ctr, Dallas, TX 75235 USA

来源：

JOURNAL OF HUMAN HYPERTENSION | 2000年 / 14卷 / Suppl 1期

关键词：

angiotensin II; angiotensin-converting enzyme inhibitors; angiotensin II-receptor blockers;

D O I：

10.1038/sj.jhh.1000992

中图分类号：

R6 [外科学];

学科分类号：

1002 [临床医学]; 100210 [外科学];

摘要：

In the past few years, angiotensin II-receptor blockers have become available and are being heavily marketed and increasingly used. In various ways they differ from angiotensin-converting enzyme inhibitors (ACEIs). Until outcome data are available, they should continue to be used primarily in patients who should receive an ACEI but cannot tolerate the drug because of cough.

引用

收藏

页码：S87 / S90

页数：4

相关论文

共 21 条

[1]

[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]

[2]

Chalmers J, 1999, J HYPERTENS, V17, P151

[3]

Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients [J].

Fogari, R ;

Zoppi, A ;

Corradi, L ;

Lazzari, P ;

Mugellini, A ;

Lusardi, P .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (05) :467-471

[4]

Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors [J].

Franz, IW ;

Tönnesmann, U ;

Müller, FM .

AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (06) :631-639

[5]

Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects [J].

Gainer, JV ;

Morrow, JD ;

Loveland, A ;

King, DJ ;

Brown, NJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (18) :1285-1292

[6]

Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension [J].

Gillies, LK ;

Werstiuk, ES ;

Lee, RMKW .

JOURNAL OF HYPERTENSION, 1998, 16 (04) :477-486

[7]

BIOCHEMICAL EFFECTS OF LOSARTAN, A NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS [J].

GOLDBERG, MR ;

BRADSTREET, TE ;

MCWILLIAMS, EJ ;

TANAKA, WK ;

LIPERT, S ;

BJORNSSON, TD ;

WALDMAN, SA ;

OSBORNE, B ;

PIVADORI, L ;

LEWIS, G ;

BLUM, R ;

HERMAN, T ;

ABRAHAM, PA ;

HALSTENSON, CN ;

LO, MW ;

LU, H ;

SPECTOR, R .

HYPERTENSION, 1995, 25 (01) :37-46

[8]

Reversible dysgeusia attributed to losartan [J].

Heeringa, M ;

van Puijenbroek, EP .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (01) :72-72

[9]

Preclinical pharmacology of angiotensin II receptor antagonists - Update and outstanding issues [J].

Johnston, CI ;

Risvanis, J .

AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) :306S-310S

[10]

KAPLAN NM, 1998, CLIN HYPERTENSION, P181